Matthew Ros, former EVP, Chief Strategy & Business Officer of Epizyme, joins Fore as Chief Executive Officer and Director of the Board
Fore Biotherapeutics (or the “Company”), a clinical-stage biotechnology company focused on precision oncology, today announced the appointment of Matthew E. Ros as the Chief Executive Officer and Director of the Board.
Mr. Ros is a 30-year veteran of the biotechnology industry. Prior to joining Fore, he was the Executive Vice President and Chief Strategy and Business Officer of Epizyme, Inc., a commercial-stage and publicly traded biopharmaceutical company developing novel epigenetic therapies. He has experience building and leading teams across sales, marketing, franchise strategy and business operations. Prior to joining Epizyme, Mr. Ros served as Chief Operating Officer and Global Head of the Oncology Business Unit at Sanofi-Genzyme and held leadership positions at ARIAD Pharmaceuticals. Mr. Ros began his career at Bristol Myers Squibb, where he held positions of increasing responsibility in its Oncology division, contributing to the successful launches of many leading cancer therapies.
Dieter Weinand, the Chairman of the Board of Directors commented: “After an extensive search, we are delighted and very excited to welcome Matt as our next CEO. Matt brings enormous experience to grow and scale Fore as an innovative biotech given his track record of success in both mature and emerging life sciences companies. He is the right leader for our company, and the Board and I are delighted to partner with Matt to navigate Fore’s path to continued success.”
“I am honored and humbled to lead Fore and work alongside the incredibly talented management team to build upon what has been accomplished to date. Fore is poised to develop targeted treatments that fundamentally transform the way cancer is treated. The company’s functional genomics platform provides us with the opportunity to serve cancer patients with novel, innovative medicines,” said Mr. Ros.
The Company expects to complete enrollment to its Phase 1/2a study in the coming months, and to launch a registrational Phase 2 study of its clinical Class I/II BRAF inhibitor, FORE8394. Additionally, using an integrated functional genomics and machine learning drug discovery engine, the Company characterizes a wide range of mutations across validated oncological targets and in-licenses clinical-stage small molecule assets to develop for hyper-targeted populations.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.
